Financial News
Articles published by Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2023
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
October 07, 2023
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
September 26, 2023
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
September 11, 2023
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
September 06, 2023
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2023
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering
April 13, 2023
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
April 12, 2023
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.